Riskpilot← Back to searchSign inGet full accessPharmaforce ApS
APSActiveCVR 26394198Frederiksborggade 15, 3.Wholesale of other food · NACE 4638Est. 20015 employeeswww.pharmaforce.dk
Revenue 2025
DKK 5,2M
-4% vs 2024
EBITDA margin
22.4%
-40% vs 2024
Equity ratio
65.9%
Financial strength
Net profit 2025
DKK 914K
-39% vs 2024
| Revenue | DKK 5,2M | -4% |
| EBITDA | DKK 1,2M | -40% |
| Net profit | DKK 914K | -39% |
| Total assets | DKK 6,6M | +7% |
| Equity | DKK 4,3M | +11% |
| Employees | 5 | — |
Legal name
Pharmaforce ApS
CVR number
26394198
Legal form
Anpartsselskab
NACE code
4638 · Wholesale of other food
Founded
29. december 2001
Share capital
DKK 125.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at udøve virksomhed med handel, investering og service samt aktiviteter i tilknytning hertil.
Address
Frederiksborggade 15, 3.
Phone
+4570272747
Website
www.pharmaforce.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 4.202 | 3.640 | 3.682 | 5.437 | 5.239 |
| Staff expenses | -3.736 | -3.204 | -3.328 | -3.480 | -4.067 |
| EBITDA | 465 | 425 | 344 | 1.957 | 1.171 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 465 | 425 | 344 | 1.957 | 1.171 |
| Net financials | 13 | -54 | 1 | -14 | 11 |
| Profit before tax | 478 | 370 | 345 | 1.943 | 1.182 |
| Tax | 111 | 88 | 83 | 448 | 268 |
| Net profit | 367 | 283 | 262 | 1.494 | 914 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 6.776 | 5.635 | 4.787 | 6.169 | 6.573 |
| Equity | 2.875 | 2.858 | 2.920 | 3.915 | 4.329 |
| Long-term debt | 144 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.757 | 2.777 | 1.866 | 2.255 | 2.244 |
| Total debt | 3.901 | 2.777 | 1.866 | 2.255 | 2.244 |
EBITDA margin
22.4%
This company
15.8%
Market median
+42% vs market
20212025
Equity ratio
65.9%
This company
38.2%
Market median
+73% vs market
20212025
Return on equity
21.1%
This company
18.4%
Market median
+15% vs market
20212025
Net profit margin
17.5%
This company
8.1%
Market median
+116% vs market
20212025
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
20212025
Debt / equity
0.52×
This company
0.62×
Market median
+16% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
HJ Founder | Founder | 2001 |
ML Chief Executive Officer | Chief Executive Officer | 2014 |
| Former (2) | ||
LD Management | Management | 2008 – 2014 |
BT Audit | Audit | 2001 – 2002 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2017 | |
| Individual | 100% | 100% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pfam Holding ApS
Pharmaforce ApS Board members of Pharmaforce ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hanne Jungdal Dannulat | Founder | 0 companies |
| Mads Louie Frazier | Chief Executive Officer | 0 companies |
| Lasse Dannulat | Management | 0 companies |
| Britta Thomsen | Audit | 0 companies |